Research Publication Repository

http://publications.wehi.edu.au/search/SearchPublications

This is the author's peer reviewed manuscript version of a work accepted for publication.

Changes introduced as a result of publishing processes such as copy-editing and formatting may not be reflected in this manuscript.

Characterization of a novel human BFL-1-specific monoclonal antibody

Lahiru Gangoda[1,2], Charis E. Teh[1,2], Michael A. Dengler[1,2], Sarah A. Best[1,2], Clare E. Weeden[1,2], Lin Tai[1,2], Erinna F. Lee[3,4,5], Walter D. Fairlie[3,4,5], Kate D. Sutherland[1,2], Leonard C. Harrison[1,2], Daniel H. Gray[1, 2], Andreas Strasser[1,2] and Marco J. Herold*[1,2]

[1] Walter and Eliza Hall Institute of Medical Research, 1 G Royal Parade, Parkville, Melbourne, Victoria 3052, Australia

[2] Department of Medical Biology, University of Melbourne, Parkville, Melbourne, Victoria 3010, Australia

[3] La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3086, Australia

[4] Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, 3084, Australia

[5] School of Cancer Medicine, La Trobe University, Melbourne, Victoria, 3086, Australia

* Correspondence to: Marco J. Herold, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia. Tel: +61 3 9345 2497 or +61 3 9345 2555; Fax: +61 3 9347 0852; E-mail: herold@wehi.edu.au

BFL-1 is the least studied pro-survival BCL-2 family member, partly due to the lack of high-quality tools, such as antibodies that can detect this protein at endogenous levels. *BFL-1* mRNA expression may not mirror BFL-1 levels due to post-translational regulation of this protein[1, 2]. Hence, there is a requirement for a reliable antibody to detect endogenous BFL-1 in cells.

To generate BFL-1-specific monoclonal antibodies, we utilized mice lacking A1 (the mouse homologue of BFL-1)[3,4]. We hypothesized that $A1^{-/-}$ mice would generate a better immune response against BFL-1 as their immune cells have not been tolerized to the highly homologous mouse A1 protein. Hence, we immunised the mice with a truncated recombinant BFL-1 protein (aa1-151, lacking the C terminal region) and two KLH-conjugated peptides corresponding to the BFL-1 protein regions aa71–84 and aa129–154. One BFL-1 reactive monoclonal antibody identified in an ELISA screen (data not shown) was validated by Western blot analysis of lysates from HEK293T cells overexpressing FLAG-tagged BFL-1 protein[5] (Supplementary Figure 1). To verify the specificity of the BFL-1 antibody, we examined BFL-1 protein stability in M14 (previously shown to express BFL-1 protein[6]) and SK-MEL30 melanoma cells. As expected, the protein synthesis inhibitor cyclohexamide (CHX) decreased and the proteasome inhibitor (MG132) increased the intensity of the BFL-1 protein band (Supplementary Figure 2). To test the cross-reactivity of the BFL-1-specific antibody for its murine counterpart A1, lysates from LPS (known to upregulate *A1* mRNA[7]) stimulated lung tissues were analysed by Western blotting. Lysates from BFL-1 CRISPR deleted[8] and parental M14 cells served as controls. This demonstrated the reactivity of the monoclonal antibody to human BFL-1 but not mouse A1 (Supplementary Figure 3).

Importantly, the BFL-1 antibody could robustly be used for BFL-1 immunoprecipitation (Figure 1a) and for immunofluorescence staining in M14 cells (Supplementary Figure 4 and Figure 1b). To validate the results in the immunofluorescence setting, 2 h treatment of M14 cells with CHX or MG132 decreased or slightly increased, respectively, the APC signal corresponding to the BFL-1 protein (Figure 1b). Mitotracker Orange was added to the serum-free growth medium for 1 h before fixation, permeabilization and antibody staining. Notably, the BFL-1 protein was predominantly present in the cytosol and did not co-localize with the mitochondrial staining, consistent with the reported sub-cellular localization of A1, its mouse homologue[1]. Unfortunately, the BFL-1 antibody did not yield reproducible results in flow cytometry experiments (data not shown).

To validate the applicability of the monoclonal BFL-1 antibody in primary human cells, peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors, stimulated in culture for 3 days with antibodies against CD3 and CD28 (known to increase the A1 protein expression in mouse T cells[4, 9]) and cell lysates subjected to Western blot analysis. Importantly, we could detect a band corresponding to the correct molecular weight of BFL-1 in stimulated samples but not in the unstimulated cells (Supplementary Figure 5). To examine whether BFL-1 protein corresponds to *BFL-1* mRNA expression, Western blot analysis and quantitative PCR analysis were performed side-by-side on a human cell line panel (Figure 1c). Since BFL-1 protein is regulated by ubiquitin-dependent proteasomal degradation[1], *BFL-1* mRNA expression data failed to fully reflect BFL-1 protein expression. The discrepancy between transcription and protein levels of BFL-1 emphasizes the importance of having a reliable BFL-1 specific antibody. Collectively, our studies describe a robust human BFL-1-specific monoclonal antibody capable of reliably detecting endogenous BFL-1 protein in cell lines and primary human cells. This antibody will enable further studies into the regulation of BFL-1 protein in homeostasis and disease.

1. Herold MJ, Zeitz J, Pelzer C, Kraus C, Peters A, Wohlleben G*, et al.* The stability and anti-apoptotic function of A1 are controlled by its C terminus. *J Biol Chem* 2006, **281**(19)**:** 13663-13671.

2. Kucharczak JF, Simmons MJ, Duckett CS, Gelinas C. Constitutive proteasome-mediated turnover of Bfl-1/A1 and its processing in response to TNF receptor activation in FL5.12 pro-B cells convert it into a prodeath factor. *Cell Death Differ* 2005, **12**(9)**:** 1225-1239.

3. Schenk RL, Tuzlak S, Carrington EM, Zhan Y, Heinzel S, Teh CE*, et al.* Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment. *Cell Death Differ* 2017, **24**(3)**:** 534-545.

4. Tuzlak S, Schenk RL, Vasanthakumar A, Preston SP, Haschka MD, Zotos D*, et al.* The BCL-2 pro-survival protein A1 is dispensable for T cell homeostasis on viral infection. *Cell Death Differ* 2017, **24**(3)**:** 523-533.

5. Lang MJ, Brennan MS, O'Reilly LA, Ottina E, Czabotar PE, Whitlock E*, et al.* Characterisation of a novel A1-specific monoclonal antibody. *Cell death & disease* 2014, **5:** e1553.

6. Lee EF, Harris TJ, Tran S, Evangelista M, Arulananda S, John T*, et al.* BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. *Cell Death Dis* 2019, **10**(5)**:** 342.

7.   Ottina E, Tischner D, Herold MJ, Villunger A. A1/Bfl-1 in leukocyte development and cell death. *Exp Cell Res* 2012, **318**(11)**:** 1291-1303.

8.   Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G*, et al.* The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. *Nature* 2016, **538**(7626)**:** 477-482.

9.   Koenen P, Heinzel S, Carrington EM, Happo L, Alexander WS, Zhang JG*, et al.* Mutually exclusive regulation of T cell survival by IL-7R and antigen receptor-induced signals. *Nat Commun* 2013, **4:** 1735.

10.   Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, Huang DC*, et al.* In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. *P Natl Acad Sci U S A* 2008, **105**(46)**:** 17961-17966.

Figure 1 A novel BFL-1 specific monoclonal antibody reliably detects this pro-survival BCL-2 family member, even at endogenous levels. (a) For immunoprecipitation experiments, pre-cleared melanoma cell (M14 and M14 BFL-1 KO) lysates were incubated overnight with BFL-1 antibody or an Ig isotype-matched control antibody (IgG2a/κ) and protein G-sepharose beads. Immunoprecipitation of MCL-1 was performed with a previously characterized MCL-1-specific monoclonal antibody (19C4-15 clone[10]) as a positive control for the immunoprecipitation protocol. The immunoprecipitated proteins were then subjected to electrophoresis and Western blotting. (b) M14 melanoma cells grown overnight on coverslips were treated for 2 h with cycloheximide or MG132 and stained with the primary antibody (anti-BFL-1 or Ig isotype matched control antibody at 25 μg/mL) and subsequently with anti-mouse IgG specific secondary antibodies conjugated to APC (red). Nuclei were stained with DAPI (blue) and slides mounted for confocal imaging. Mitotracker Orange was added to cells prior to fixation to stain for mitochondria. Scale bars indicate 20 microns. (c) The monoclonal antibody against BFL-1 detects BFL-1 at endogenous levels in a panel of human melanoma, mantle cell (MCL) and other B cell lymphoma (BCL) derived cell lines by Western blotting. Probing for HSP70 served as a protein loading control (left side). Total RNA was extracted from the same cell lines and converted to cDNA. RT-PCR analysis was performed using Taqman probe sets for the house-keeping gene *HMBS* and *BFL-1* with relative quantification applied using the ΔCt method (right side).

Figure 1

a

b

c